glutathione cisplatin cytotoxicity

glutathione cisplatin cytotoxicity Overcoming resistance to by inhibition of S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo The role of the Nrf2/GSH

Name: glutathione cisplatin cytotoxicity Overcoming resistance to by inhibition of S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo The role of the Nrf2/GSH
Brand: aimoneimmobiliare.it
SKU: 85645875857
Price: 24.06 USD
Availability: InStock
Rating: 4.549 (27 reviews)

The role of the Nrf2 GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours Journal of Cancer Research and Clinical Oncology Springer Nature Link The balance between NRF2 GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells Scientific Reports A structure based mechanism of cisplatin resistance mediated by glutathione transferase P1 1 PNAS Glutathione boosting the cytotoxicity of a magnetic platinum( iv ) nano prodrug in tumor cells Chemical Science (RSC Publishing) DOI:10.1039 C5SC04049C Multi Omics Analysis Reveals Chronic Cisplatin Exposure Is Associated with Metabolic Rewiring Toward Glutathione Metabolism to Support Redox Adaptation in High Grade Serous Ovarian Cancer

SKU: 85645875857 · From aimoneimmobiliare.it

4.5

USD24.06 USD57.06

Pay in 4 interest-free payments of $6.01 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 6 - Aug 11

Description

& Chwatko, G

2006 Cortisol, thyroid hormones, and prolactin remain unaffected across all doses tested confirming selective GHRH receptor agonism without hypothalamicpituitaryadrenal axis activation

Viability assay AML cells were plated at 20x10 4 /mL in 100 l of 10% FBSsupplemented RPMI prior to the addition of compounds

Periasamy et al., Amino acids functionalized inorganic metal nanoparticles: synthetic nanozymes for target specific binding, sensing and catalytic applications, in Nanozymes for Environmental Engineering

J Agric Food Chem 55:52465252 Strayer DR, Carter WA, Stouch BC et al (2012) A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome